IP Library Granted Patent US 9,409,896
Granted Patent B2
US 9,409,896 · App. 13/882,698 · Granted Aug 9, 2016

Sustained release pharmaceutical compositions comprising an antibacterial agent

Inventors: Eric S. Burak (East Haddam, CT); Danping Li (Middlebury, CT); David S. Dresback (Stonington, CT)
Assignee: Melinta Therapeutics, Inc.
C07D413/12A61K9/205A61K9/2018A61K9/2054A61K9/2059A61K9/4858A61K9/4866A61K31/4192A61K31/421A61K31/5375A61K47/14A61K47/22C07D263/22C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,409,896
App. No.
13/882,698
Granted
Aug 9, 2016
Kind
B2
Abstract

The present invention relates to carrier systems useful for pharmaceutical compositions. These carriers comprise an emulsifier, and also in further embodiments a polymeric dissolution aid. These carriers are useful for delivering pharmaceutical actives such as antimicrobial agents.

Claims (17)

1. A pharmaceutical composition comprising an antimicrobial agent, a pharmaceutical carrier, an emulsifier, and a polymeric dissolution aid, wherein said antimicrobial agent is

(S)—N-((3-(4′-((((1H-1,2,3-triazol-5-yl)methyl)amino)methyl)-2-fluoro-[1,1′-biphenyl]-4-yl)-2-oxooxazolidin-5-yl)methyl)acetamide,

or a pharmaceutically acceptable salt or tautomer thereof.

2. The pharmaceutical composition according to claim 1 wherein said emulsifier is a polyglycolized glyceride.

3. The pharmaceutical composition according to claim 2 wherein said emulsifier is selected from the group consisting of Labrafil, Labrosol, and Gelucire.

4. The pharmaceutical composition according to claim 3 wherein said emulsifier is selected from the group consisting of Gelucire 50/13, Gelucire 44/14, and mixtures thereof.

5. The pharmaceutical composition according to claim 1 wherein said polymeric dissolution aid is selected from the group consisting of polymers of 1-ethenyl-2-pyrrolidinone; polyamine N-oxide polymers; copolymers of N-vinylpyrrolidone and N-vinylimidazole; polyvinyloxazolidones and polyvinylimidazoles or mixtures thereof.

6. The pharmaceutical composition according to claim 5 wherein said polymeric dissolution aid is a polymer of 1-ethenyl-2-pyrrolidinone.

7. The pharmaceutical composition according to claim 5 wherein said polymeric dissolution aid is polyvinylpyrrolidone.

8. The pharmaceutical composition according to claim 1 further comprising a binder, filler, dispersant or wetting agent, disintegrant, or lubricant.

9. The pharmaceutical composition according to claim 1 further comprising one or more components selected from the group consisting of water, a nonaqueous solvent, a coating, a capsule shell, a colorant, a flavoring, a preservative, an antioxidant, a flavor enhancer, a compression aid, and a surfactant.

10. The pharmaceutical composition according to claim 1 in the form of a tablet.

11. The pharmaceutical composition according to claim 1 in the form of a capsule.

12. A method of treating or reducing the risk of a microbial infection in a patient comprising administering a pharmaceutically effective amount of a pharmaceutical composition according to claim 1 .

13. The method of claim 12 wherein the patient is a mammal or a domestic animal.

14. The method according to claim 12 wherein the composition, compared to a control composition, provides at least a 5% improvement in dissolution in a two step dissolution testing system.

15. The method according to claim 14 wherein the two step dissolution system comprises measuring the dissolution in a first step in a simulated gastric environment of about pH 4 for up to 30 minutes followed by measuring the dissolution in a second step in a simulated gastric environment of about pH 5.4 to about 6.5 for up to about 60 minutes.

Assignments (7)
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT (PATENTS) AT REEL 054836 AND FRAME 0824, REEL 061314 AND FRAME 0572 AND REEL 068260 AND FRAME 0283 Recorded Aug 29, 2025
From: SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 074576/0471 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 25, 2022
From: MELINTA SUBSIDIARY CORP.
To: SILICON VALLEY BANK
Reel/Frame 061314/0572 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 22, 2020
From: MELINTA SUBSIDIARY CORP.
To: SILICON VALLEY BANK
Reel/Frame 054836/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2019
From: MELINTA THERAPEUTICS, INC.
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 048030/0489 →
SECURITY INTEREST Recorded Jan 8, 2018
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; CEM-102 PHARMACEUTICALS, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 045019/0552 →
CHANGE OF NAME Recorded Jan 7, 2014
From: RIB-X PHARMACEUTICALS, INC.
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 031934/0039 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2013
From: BURAK, ERIC S.; LI, DANPING; DRESBACK, DAVID S.
To: RIB-X PHARMACEUTICALS, INC.
Reel/Frame 030495/0267 →
Continuity (2)
Provisional Application 61408830 · Nov 1, 2010
Related Publication 20140094463A1 · Apr 3, 2014